Clinical experience with daptomycin in Europe: the first 2.5 years

To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes.Data from the European Cubicin Outcomes Registry and Experience (EU-CORESM), retrospectively collected at 118 institutions between January 2006 and August 2008, were analysed.Daptomycin treatment was documented in 1127 patients with diverse infections, including complicated skin and soft tissue infections (33%),...